Active — Not RecruitingNot Applicable

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

41 participantsStarted 2015-06

Plain-language summary

Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject. The study is a non-interventional, follow-up study of subjects who participated in previous AAV2-hRPE65v2 gene therapy clinical trials.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Subjects who will not consent for study.
✕. Subjects who the investigators believe are not capable of performing study assessments

What they're measuring

Mobility testing, Bilateral

Timeframe: 15 years

Trial details

NCT IDNCT03602820

SponsorSpark Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-01

View on ClinicalTrials.gov More Inherited Retinal Dystrophy Due to RPE65 Mutations trials